These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 21614073)

  • 1. A 2020 vision for vaccines against HIV, tuberculosis and malaria.
    Rappuoli R; Aderem A
    Nature; 2011 May; 473(7348):463-9. PubMed ID: 21614073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectious disease: Beating the big three.
    Bourzac K
    Nature; 2014 Mar; 507(7490):S4-7. PubMed ID: 24611168
    [No Abstract]   [Full Text] [Related]  

  • 3. A decade of vaccines: Integrating immunology and vaccinology for rational vaccine design.
    D'Argenio DA; Wilson CB
    Immunity; 2010 Oct; 33(4):437-40. PubMed ID: 21029955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Convergent ethical issues in HIV/AIDS, tuberculosis and malaria vaccine trials in Africa: Report from the WHO/UNAIDS African AIDS Vaccine Programme's Ethics, Law and Human Rights Collaborating Centre consultation, 10-11 February 2009, Durban, South Africa.
    Mamotte N; Wassenaar D; Koen J; Essack Z
    BMC Med Ethics; 2010 Mar; 11():3. PubMed ID: 20211030
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined efforts in immunology and vaccinology will lead to effective vaccines against HIV, tuberculosis and malaria.
    Chiodi F; Kaufmann SH
    J Intern Med; 2014 May; 275(5):442-3. PubMed ID: 24635534
    [No Abstract]   [Full Text] [Related]  

  • 6. Vaccines for the 21st century.
    Delany I; Rappuoli R; De Gregorio E
    EMBO Mol Med; 2014 Jun; 6(6):708-20. PubMed ID: 24803000
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genome-based vaccine design: the promise for malaria and other infectious diseases.
    Doolan DL; Apte SH; Proietti C
    Int J Parasitol; 2014 Oct; 44(12):901-13. PubMed ID: 25196370
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prime-boost immunization strategies for infectious diseases.
    McShane H
    Curr Opin Mol Ther; 2002 Feb; 4(1):23-7. PubMed ID: 11883691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in tuberculosis vaccine strategies.
    Skeiky YA; Sadoff JC
    Nat Rev Microbiol; 2006 Jun; 4(6):469-76. PubMed ID: 16710326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospects for vaccines to protect against AIDS, tuberculosis, and malaria.
    Letvin NL; Bloom BR; Hoffman SL
    JAMA; 2001 Feb; 285(5):606-11. PubMed ID: 11176867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Understanding protective immune mechanisms induced by malaria vaccines in the context of clinical trials.
    Dobaño C; Campo JJ
    Hum Vaccin; 2009 Aug; 5(8):562-5. PubMed ID: 19287202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tuberculosis DNA vaccine in an HIV-1 p24 protein backbone confers protection against Mycobacterium tuberculosis and simultaneously elicits robust humoral and cellular responses to HIV-1.
    Li X; Xu W; Xiong S
    Clin Vaccine Immunol; 2012 May; 19(5):723-30. PubMed ID: 22461526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The March Toward Malaria Vaccines.
    Hoffman SL; Vekemans J; Richie TL; Duffy PE
    Am J Prev Med; 2015 Dec; 49(6 Suppl 4):S319-33. PubMed ID: 26590432
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Accelerating next-generation vaccine development for global disease prevention.
    Koff WC; Burton DR; Johnson PR; Walker BD; King CR; Nabel GJ; Ahmed R; Bhan MK; Plotkin SA
    Science; 2013 May; 340(6136):1232910. PubMed ID: 23723240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The Global Fund to fight HIV/AIDS, TB and Malaria 5-y: evaluation policy issues].
    Kerouedan D
    Bull Soc Pathol Exot; 2010 May; 103(2):119-22. PubMed ID: 20376595
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines under development: group B streptococcus, herpes-zoster, HIV, malaria and dengue.
    da Silva LJ; Richtmann R
    J Pediatr (Rio J); 2006 Jul; 82(3 Suppl):S115-24. PubMed ID: 16721441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early phase clinical trials with human immunodeficiency virus-1 and malaria vectored vaccines in The Gambia: frontline challenges in study design and implementation.
    Afolabi MO; Adetifa JU; Imoukhuede EB; Viebig NK; Kampmann B; Bojang K
    Am J Trop Med Hyg; 2014 May; 90(5):908-14. PubMed ID: 24615122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A systematic review of safety data reporting in clinical trials of vaccines against malaria, tuberculosis, and human immunodeficiency virus.
    Tamminga C; Kavanaugh M; Fedders C; Maiolatesi S; Abraham N; Bonhoeffer J; Heininger U; Vasquez CS; Moorthy VS; Epstein JE; Richie TL
    Vaccine; 2013 Aug; 31(35):3628-35. PubMed ID: 23395586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances and challenges in recombinant Mycobacterium bovis BCG-based HIV vaccine development: lessons learned.
    Kilpeläinen A; Maya-Hoyos M; Saubí N; Soto CY; Joseph Munne J
    Expert Rev Vaccines; 2018 Nov; 17(11):1005-1020. PubMed ID: 30300040
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.